Sign In
Buy BMY
$54.72
+0.260 (+0.477%)
At Close: Jun 03, 2026
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?
02:30am, Thursday, 04'th Jun 2026
Durability, not yield, is the deciding factor.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
10:00am, Wednesday, 03'rd Jun 2026
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for
Bristol Myers vs. Pfizer: Which High‑Yield Dividend Stock Wins Now?
03:45am, Wednesday, 03'rd Jun 2026
Both are working hard to get around patent cliffs. One of them seems to have made more progress on that front.
Recursion Pharmaceuticals vs. Schrödinger: Which Healthcare Stock Is a Better Buy in 2026?
05:12pm, Tuesday, 02'nd Jun 2026
Two AI-driven disruptors, one biotech-focused, one software-first, post double-digit growth but diverge sharply on risk, cash flow, and valuation.
BMY Gets Opdivo Label Expansion in the EU, Update on Camzyos
02:01pm, Tuesday, 02'nd Jun 2026
Bristol Myers secured EU approval for Opdivo plus AVD in newly diagnosed advanced cHL and advanced Camzyos' label expansion review.
Bristol Myers Squibb: This Pullback Is A Gift For Long-Term Investors
10:59am, Tuesday, 02'nd Jun 2026
Bristol Myers Squibb offers a compelling buy-the-dip opportunity with a forward P/E of 8.7x and a 4.6% dividend yield. BMY's diversified growth portfolio posted 9% YoY sales expansion, offsetting lega
REDMOND, Wash. & PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #ASCO--Izalontamab Brengitecan (Iza-Bren) Demonstrates Statistically Significant and Clinically Meaningful Improvements in Overall Survival.
Bristol Myers' Growth Portfolio Just Overtook The Legacy One
04:23am, Tuesday, 02'nd Jun 2026
Bristol Myers Squibb is mispriced as a melting ice cube, despite its Growth Portfolio surpassing Legacy revenues in Q1 2026. BMY's pipeline offers four near-term catalysts—including iberdomide, mezi
Why Bristol Myers Squibb Stock Isn't Nearly As Cheap As It Looks
11:15pm, Monday, 01'st Jun 2026
Bristol Myers Squibb has an attractive 4.4% yield, and its 16x P/E is below the pharma average of 24x.
Bristol Myers Showcases Data on MM and NSCLC Drugs at ASCO
11:01am, Monday, 01'st Jun 2026
BMY unveils strong ASCO data for mezigdomide and pumitamig, highlighting late-stage pipeline progress across myeloma and lung cancer.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #CAMZYOS--US FDA Accepts for Priority Review Bristol Myers Squibb's Supplemental New Drug Application for Camzyos to Treat Adolescents with oHCM.
PRINCETON, N.J.--(BUSINESS WIRE)---- $BMY #HodgkinLymphoma--BMS Announces Opdivo (nivolumab) in Combination with AVD Receives Expanded EU Label with Approval in Frontline Advanced Classical Hodgkin Ly
Erster bispezifischer PD-(L)1xVEGF-Immunmodulator-Kandidat, zu dem globale Daten mit ermutigender Wirksamkeit in Kombination mit Chemotherapie in der Erstlinienbehandlung von nicht-kleinzelligem Lunge
First investigational PD-(L)1xVEGF bispecific immunomodulator to present global data showing encouraging efficacy in combination with chemotherapy in first-line non-small cell lung cancer across PD-L1
